FTC commissioners dig into Impax settlement
The Federal Trade Commission’s members have questioned both sides about the balance of costs and benefits in Impax Laboratories’ reverse-payment settlement with Endo Pharmaceuticals – in the first oral arguments hearing since the agency added five new members.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10